Drug: Buprenorphine transdermal patch: chronic pain clinical trials

Registry records that list "Drug: Buprenorphine transdermal patch" as an intervention. Being studied does not mean an intervention works or is approved.

Trials with Canadian sites

Recruiting in Canada

Registry records in total

Trials in Canada

No trial with a Canadian site lists this intervention in this snapshot.

Trials worldwide (outside Canada)

11 trials, 0 recruiting or not yet recruiting. Recruiting first.

		Phase	Countries
Buprenorphine Transdermal Patches Pharmacokinetic Study NCT03975010	Unknown status	Phase 1	China	Mundipharma (China) Pharmaceutical Co. Ltd	2019-05-13
Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain NCT01961271	Completed	Phase 4	Hong Kong, Philippines, South Korea	Mundipharma Pte Ltd.	2013-06
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 NCT01125917	Terminated	Phase 3	United States	Purdue Pharma LP	2004-06
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 NCT01125917	Terminated	Phase 3	United States	Purdue Pharma LP	2004-06
Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 NCT01125917	Terminated	Phase 3	United States	Purdue Pharma LP	2004-06
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase. NCT00320801	Terminated	Phase 3	United States	Purdue Pharma LP	2004-01
Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase. NCT00320801	Terminated	Phase 3	United States	Purdue Pharma LP	2004-01
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee NCT00313846	Completed	Phase 3	United States	Purdue Pharma LP	2003-04
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study NCT01151098	Completed	Phase 3	United States	Purdue Pharma LP	2001-04
Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain NCT00312195	Completed	Phase 3	United Kingdom, United States	Purdue Pharma LP	2001-03
The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain. NCT00315445	Completed	Phase 3	United States	Purdue Pharma LP	1997-12

Conditions studied with this intervention

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.